AI x Biology Workshop
2025

Tom Roseberry spent many years as an engineer in aerospace manufacturing before developing a strong interest in neuroscience through racing endurance sports. While working as a triathlon coach he retrained as a biologist followed by a PhD in neuro at UCSF. After a brief postdoc, he left academia to work at Neuralink on next-generation brain-machine interfaces. Through a series of startups he gravitated towards drug development, recently as the VP of Engineering, Comp Bio and Drug Development at Loyal. He recently co-founded Olio Labs, which leverages AI to design combination therapeutics with improved efficacy and fewer side effects.

​Seth Paulson is a seasoned software developer with extensive experience in bioinformatics and computational biology. At the Methuselah Foundation, he contributes to advancing regenerative medicine and extending healthy human lifespan. Seth leads the development of the Biolearn program for the Biomarkers of Aging Consortium, an open-source library dedicated to the implementation and application of aging biomarkers. His expertise in software development and bioinformatics plays a pivotal role in harmonizing existing biomarkers and unifying public datasets to facilitate cross-population validation studies.

Yisong Yue is a professor of Computing and Mathematical Sciences at the California Institute of Technology (Caltech), specializing in the theory and application of statistical machine learning. His research focuses on developing novel methods for interactive and structured machine learning, with applications spanning information retrieval, robotics, and experiment design. In addition to his academic role, Yisong serves as an advisor at Asari AI, where he contributes to designing AI agents capable of complex planning, abstraction, and verification tasks, facilitating collaboration between humans and AI systems.

Stephen Malina is a machine learning engineer and scientist working at the intersection of AI and gene therapy. He is the ML Engineering Lead at Dyno Therapeutics, where he develops and scales machine learning systems that accelerate the design of next-generation AAV gene therapy vectors. His work supports Dyno’s mission to reshape the gene therapy landscape through AI-powered precision. Stephen’s background spans both industry and academic research. He previously served as Dyno’s Head of Engineering and was the Principal Scientist leading the Machine-Guided Design Team. He also conducted research as a Graduate Research Assistant in the Knowles Lab, focusing on applying ML to molecular discovery. Before joining Dyno, Stephen built scalable backend infrastructure as a Senior Software Engineer at Uber and Compass, where he developed high-performance systems for real-time data pipelines and asynchronous image processing. His unique blend of engineering expertise and scientific curiosity now drives innovation in biotech, where he aims to make gene therapies safer, more efficient, and broadly accessible.

Andrew White is a researcher with over 50 peer-reviewed publications and books across the domains of large language models in chemistry, explainable artificial intelligence, statistical mechanics, and chemical engineering. He has won junior investigator awards from the National Science Foundation and National Institutes of Health along with professional and teaching awards for excellence as a chemical engineer. Andrew is an active member of the scientific community as a peer reviewer for over 30 journals, multiple national and private grant awarding institutions, and serves on the Chemical Sciences Roundtable at the National Academy of Science. Andrew is also a science communicator with large followings on X and LinkedIn and has been interviewed in multiple publications such as the New York Times, Bloomberg, Nature, Financial Times, and Science. Andrew serves on multiple scientific advisory boards across biotech. He has contributed to the ongoing debate around safety of artificial intelligence as a GPT-4 red teamer, speaking at multiple policy summits, and visiting the White House to advise multiple agencies.

John Hallman is a machine learning engineer with a robust background in artificial intelligence research and applications. Currently, he serves as a Member of the Technical Staff at OpenAI, contributing to the development of advanced AI models. Prior to this role, John was a Machine Learning Engineer at AKASA, focusing on automating administrative tasks in healthcare to enhance efficiency and reduce costs. John's research experience includes an internship at Google Brain, where he concentrated on reinforcement learning projects. He holds a degree in mathematics from Princeton University and was awarded a silver medal in the International Mathematical Olympiad (IMO). His diverse expertise encompasses machine learning, artificial intelligence, and their practical applications across various industries.

​Fabio Boniolo is a computational scientist specializing in the application of statistical and machine learning techniques to understand complex diseases such as cancer. He is a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute of MIT and Harvard, where he focuses on pediatric brain tumors and epigenetics. Fabio earned both his B.Sc. and M.Sc. in biomedical engineering from Politecnico di Milano. He completed his Ph.D. at the Technical University of Munich, developing new methods for patient stratification in precision oncology. Actively involved in the biotech startup scene, he collaborates with various venture funds and entrepreneurial associations. In 2021, Fabio served as an Italian delegate to the G7 Youth Summit.

Erika is a former astronomer and current synthetic biologist.  In 2021 she founded The Align Foundation, a nonprofit improving the reproducibility, scalability, and shareability of life science research. Align aims to make it easy to build upon the methods and data of other scientists, allowing scientific fields to accumulate data assets to train AI models.

​Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor with over two decades of experience studying the impact of new technologies on society. She is the founder of 100 Plus Capital, Lead Venture Partner at Portfolia, and serves as an advisor to Felicis Ventures, organizations that invest at the convergence of biology and technology. Sonia focuses her efforts on exponentially growing technologies and their societal implications. Her most recent book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. Through her diverse endeavors, Sonia Arrison continues to influence the discourse on technology's role in shaping the future, particularly in the realms of human longevity and societal transformation.

Dr. Sam Rodriques is a physicist, bioengineer, and entrepreneur with extensive experience in academic research and biotechnology innovation. He is the founder and CEO of FutureHouse, a research lab in San Francisco dedicated to developing an AI Scientist to accelerate scientific discovery. Before establishing FutureHouse in 2023, Dr. Rodriques led the Applied Biotechnology Laboratory at the Francis Crick Institute, where he focused on integrating bioengineering and business to advance medical and biological research. His notable inventions include technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication. Throughout his career, Dr. Rodriques has been committed to accelerating scientific research through innovative technologies and interdisciplinary approaches. His work aims to revolutionize the pace of discovery and provide global access to cutting-edge scientific, medical, and engineering expertise.

Dr. Morgan Levine is a prominent scientist specializing in the biology of aging, with extensive experience in academic research and computational biology. She currently serves as the Vice President of Computation at Altos Labs, a biotechnology company focused on restoring cell health and resilience through cell rejuvenation. Dr. Levine's scientific background encompasses bioinformatics, cellular biology, complex systems, and biostatistics. She is renowned for developing innovative methods to quantify the molecular and physiological changes that occur over an organism's lifetime, integrating interdisciplinary approaches to track the trajectories of aging cells and organisms. Her vision includes creating multi-scale computational models to elucidate how dynamic molecular states of cells lead to health and disease manifestations at various biological levels. Her work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Alexandru Băcița is a scientist and entrepreneur with extensive experience in drug discovery and development. He is the co-founder and Chief Operating Officer of The Cat Health Company (TCHC), a biotech startup dedicated to extending feline longevity through innovative therapies. Before co-founding TCHC, Alexandru served as a Senior Scientist at Charles River Laboratories, a leading provider of services for drug discovery and clinical trials. At TCHC, Alexandru focuses on developing computational pipelines to predict new therapies for rare diseases and age-related conditions in cats. His work aims to enhance feline health and longevity, providing pets with longer, healthier lives

Matthew Osman is an entrepreneur and AI specialist with a diverse background in finance and law. He holds a degree in Philosophy, Politics, and Economics from the University of Oxford. He co-founded Legit.ai, a life science AI startup that utilized natural language processing to streamline research and development processes. Under his leadership, Legit.ai was acquired by Clora in 2020. Matthew's work focuses on integrating AI technologies across various industries to drive innovation and efficiency.

Jason Kelly is an entrepreneur and innovator with over a decade of experience in synthetic biology and biotechnology. He is the co-founder and CEO of Ginkgo Bioworks, a company pioneering the use of biological engineering to create sustainable solutions across industries. Jason's background is rooted in biological engineering and computational biology, with a focus on harnessing the power of living organisms to address global challenges. His work aims to revolutionize manufacturing, agriculture, and medicine by programming biology to create a more sustainable and healthier future.

Alexandrul-Ioan Voda, DPhil, is a passionate leader in regenerative medicine, bioinformatics, and biotech. As CEO of The Cat Health Company, Alex leverages a diverse skill set combining wet-lab and computational sciences to drive advancements in biomedical research. A coding aficionado fluent in Python, R, and Bash, Alex specializes in machine learning, data structures, and algorithms. With a DPhil from the University of Oxford, he has contributed to groundbreaking work in inflammatory bowel disease genetics, aging clocks, and human health. His experience spans both academic and industry sectors, with a strong focus on innovation and scientific leadership.

John Cumbers is a British molecular biologist and entrepreneur based in the San Francisco Bay Area. He is the founder and CEO of SynBioBeta, an organization that promotes synthetic biology to build a more sustainable universe. John also founded BetaSpace, a space settlement innovation network, and is an operating partner at DCVC, a venture capital firm focused on biotechnology investments. His work at NASA and his contributions to synthetic biology have earned him multiple awards and recognition in the field.

Derya Unutmaz, MD, is a distinguished professor at The Jackson Laboratory, renowned for his pioneering work on human T cell differentiation, activation, and regulation in immunity, diseases, and aging. With a medical degree from Marmara University, Istanbul, he also holds a concurrent professorship at the University of Connecticut Health Center. Dr. Unutmaz’s research has transformed understanding of T cell dysfunction in diseases like HIV and chronic fatigue syndrome. His work aims to optimize immune responses and develop therapies that combat age-related diseases, advancing healthier aging and immune system treatments.

Alfredo Andere is the co-founder and CEO of LatchBio, a platform that provides biology companies with the tools to store, transform, and analyze large data sets. Before founding LatchBio, he worked as a Data Engineer at Facebook and a Software Engineer at Google Brain, gaining valuable experience in handling large-scale data. Alfredo and his co-founders envisioned bringing high-quality computational infrastructure to the field of biology, and they dropped out of their senior year at UC Berkeley to pursue this goal. Since its inception, LatchBio has raised significant funding and serves numerous biotech companies.

Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.

Vincent Weisser is a dedicated advocate for decentralized science and AI, known for his work on projects like VitaDAO, which funds longevity research, and Molecule, a platform for scientific funding. He is passionate about democratizing access to cutting-edge technologies and scientific progress, aiming to create a future where advanced AI and biotechnology are accessible to all. Vincent's diverse interests and contributions span across AI, biotechnology, energy, and more, making him a key figure in the tech and science communities.

Allison Duettmann is the President and CEO of the Foresight Institute, where she directs programs on Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs. She is also the Founder of Existential Hope and has co-edited works on superintelligence and co-authored books on future technologies. Allison holds an MS in Philosophy & Public Policy from the London School of Economics, focusing on AI Safety. She is a prominent advocate for leveraging technology to create a positive long-term future for humanity.

Joe Betts-LaCroix is an American scientist and entrepreneur known for his discoveries in biophysics and for creating the world's smallest personal computer. He is currently the co-founder and CEO of Retro Biosciences, a company focused on developing therapeutics to increase healthy human lifespan by ten years. Joe has a background in earth sciences, biophysics, and computer hardware, and has contributed to significant advancements in both scientific research and technology innovation.